Form 4: Aquestive Therapeutics Executive Alexander Schobel Reports Acquisition of Restricted Stock and Stock Options

Alexander Schobel, Chief Innovation/Tech Officer of Aquestive Therapeutics, reports the acquisition of 82,500 shares of restricted common stock and 41,250 non-qualified stock options.

Summary

• Alexander Mark Schobel, Chief Innovation/Tech Officer of Aquestive Therapeutics, Inc., filed a Form 4 on March 11, 2024.
• The report details transactions from March 7, 2024, including the acquisition of 82,500 shares of common stock and 41,250 non-qualified stock options.
• The common stock is represented by restricted stock vesting in three annual installments: 25% on the 1st, 25% on the 2nd, and 50% on the 3rd installment.
• The options, with an exercise price of $5.68, also vest in three annual installments: 25% on the 1st, 25% on the 2nd, and 50% on the 3rd installment, and expire on 03/07/2034.
• Following the reported transactions, Schobel beneficially owns 1,065,371 shares of common stock and 41,250 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing showing executive compensation. The acquisition of stock and options can be seen as a positive sign, but it's not overwhelmingly so.

Positives

• The acquisition of restricted stock and stock options by a key executive signals confidence in the company's future prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which can be an indicator of management's view of the company's prospects.

Stakeholder Impact

• The acquisition of shares by an executive could be viewed positively by shareholders, indicating confidence in the company's future.

Key Dates